MedTrace Logo

EuroSIDA As An External Comparator To MOTIVATE Trials

NCT01329783 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1181

Last updated 2011-05-16

No results posted yet for this study

Summary

Human Immunodeficiency Virus (HIV) infected patients who meet the entry criteria for the maraviroc pivotal trials (Maraviroc versus Optimized Therapy in Viremic Antiretroviral Treatment-Experienced Patients, MOTIVATE) will be identified from the EuroSIDA HIV cohort. The rates of specific clinical adverse events in this identified patient population will be compared with the rates of these events in the participants of the MOTIVATE trials.

Conditions

Interventions

OTHER

maraviroc

No intervention is distributed during this trial.

Sponsors & Collaborators

  • Copenhagen HIV Programme

    collaborator OTHER_GOV

  • Pfizer

    collaborator INDUSTRY

  • ViiV Healthcare

    lead INDUSTRY

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-04-30
Primary Completion
2011-03-31
Completion
2011-03-31

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01329783 on ClinicalTrials.gov